[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.172.195.82. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Research Letter
March 2011

Topical Timolol for Periocular Hemangioma: Report of Further Study

Author Affiliations

Author Affiliations: Yale University School of Medicine, New Haven, Connecticut (Ms Ni); and The Eye Institute of Ophthalmology and Visual Science, New Jersey Medical School, Newark (Drs Langer, Wagner, and Guo).

Arch Ophthalmol. 2011;129(3):373-379. doi:10.1001/archophthalmol.2011.24

Childhood superficial capillary hemangiomas of the eyelid may lead to amblyopia or anisometropia.1,2 Although benign, such tumors can cause irreversible visual loss if not treated promptly. Treatment options for infantile hemangioma include both systemic and intralesional corticosteroids, interferon alfa, laser, embolization, immunomodulators, surgery, and, most recently, propanolol.1,3 Guo and Ni4 first reported successful outcomes for a 4-month-old infant with superficial capillary hemangioma of the eyelid using topical timolol maleate application. We now report a series of 7 children in whom significant reductions of periocular and facial capillary hemangiomas occurred following topical application of timolol maleate, 0.5%, solution.

×